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ABSTRACT: The role of peroxisome proliferator-activated receptor a (PPARa)-mediated metabolic remodeling in cardiac
adaptation tohypoxiahasyet tobedefined.Here,micewerehoused inhypoxia for3wkbefore invivo contractile function
was measured using cine MRI. In isolated, perfused hearts, energetics were measured using 31P magnetic resonance
spectroscopy (MRS), and glycolysis and fatty acid oxidation were measured using [3H] labeling. Compared with a nor-
moxic, chow-fed control mouse heart, hypoxia decreased PPARa expression, fatty acid oxidation, and mitochondrial
uncouplingprotein3(UCP3)levels,whileincreasingglycolysis,allofwhichservedtomaintainnormalATPconcentrations
([ATP]) and thereby,ejectionfractions.Ahigh-fatdiet increasedcardiacPPARa expression, fattyacidoxidation,andUCP3
levelswithdecreasedglycolysis.Hypoxiawasunable toalter thehighPPARa expressionor reverse themetabolic changes
caused by the high-fat diet, with the result that [ATP] and contractile function decreased significantly. The adaptive
metabolic changes caused by hypoxia in control mouse hearts were found to have occurred already in PPARa-deficient
(PPARa2/2) mouse hearts and sustained function in hypoxia despite an inability for further metabolic remodeling. We
conclude that decreased cardiac PPARa expression is essential for adaptive metabolic remodeling in hypoxia, but is
prevented by dietary fat.—Cole, M. A., Abd Jamil, A. H., Heather, L. C., Murray, A. J., Sutton, E. R., Slingo, M., Sebag-
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Each day, the human heart beats ;100,000 times and
pumps;10 tons of blood through the body, therefore re-
quiring;6kgofATP (1). Toproduce such a large quantity
of ATP, the heart relies on mitochondrial oxidative phos-
phorylation of a variety of metabolic fuels, including free
fatty acids (FFAs) and glucose. In theory, FFAs require
;13% more oxygen than glucose to generate the same
amount of ATP, although hearts metabolizing FFAs may
require far more oxygen, owing to increased mitochon-
drial uncoupling (2, 3). ATP is transported from the mi-
tochondria to be used for contractile function via the
creatine (Cr) kinase energy shuttle, in which phosphate is
transferred from ATP to Cr with the formation of phos-
phocreatine (PCr) and ADP in a reaction catalyzed by mi-
tochondrialCr kinase (1):ATPþ Cr ↔ PCrþADPþHþ:
The Cr kinase system acts to keep ATP levels con-
stant via a fall in PCr and a rise in cytosolic free ADP
concentrations ([ADP]free), which controls mitochon-
drial oxidative phosphorylation when oxygen is not
limiting (4).
In hypoxia, when oxygen availability limits oxida-
tive phosphorylation, the heart moves toward more
oxygen-efficient carbohydrate, away from fatty acid,
metabolism (5). Thus, cardiac glucose uptake was in-
creased in hypoxic rats (6) and in high-altitude-adapted
humans (7), and fatty acid metabolizing enzyme [car-
nitine palmitoyltransferase 1 (CPT1) and medium-chain
acyl-coenzyme A dehydrogenase (MCAD)] expression
was decreased by hypoxia (8–10). Magnetic resonance
(MR) studies have shown that cardiac PCr/ATP ratios
are lower in high-altitude-adapted humans (11) and in
lowlanders returning to sea level following a trek to
Mount Everest Base Camp (12). However, the links
among limited oxygen availability, changes in substrate
metabolism,ATP generation, and cardiac function have
not been well defined.
The balance between fatty acid and glucose metab-
olism may be regulated, at least in part, by the nuclear
PPARs. Of the 3 receptor isoforms, a, d, and g, PPARa
and PPARd are highly expressed in the heart (13).
PPARa regulates several genes encoding for proteins
that control fatty acid metabolism, including MCAD
(14), and glucose metabolism, including pyruvate de-
hydrogenase kinase 4 (PDK4) and glucose transporter 4
(GLUT4) (15).
Hypoxia is a potential driver of metabolic reprogram-
ming, with the oxygen-sensitive transcriptional activator
hypoxia-inducible factor 1a (HIF-1a) elevated in ischemic
cardiac myocytes (16) and in infarcted hearts (17). In nor-
moxia, HIF-a subunits are polyubiquitinated for protea-
somal degradation, the constant degradation of HIF-a
subunits mediated by hydroxylation via the prolyl hy-
droxylasedomain (PHD)oregl-9 familyhypoxia-inducible
factor (EGLN) oxygenase family. In hypoxia, PHD activity
is reduced, stabilizing HIF-a, which translocates to the
nucleus and dimerizes with HIF-1b. The dimer transcrip-
tionally activates;200 genes, including those involved in
erythropoiesis, angiogenesis, and energy metabolism (18).
In hypoxia-adapted Tibetans, variants of the genes EGLN1
and endothelial PAS domain-containing protein 1,
encoding for PHD2 (the most important of the 3 human
PHDs) and the HIF-2a subunit, respectively, associated
with the PPARA gene in genome-wide scans (19), and
serum fatty acid concentrations in this group correlated
with the PPARAhaplotype (20). These findings suggest
that PPARamay control cardiac substrate metabolism,
ATP generation, and thereby, cardiac function in hyp-
oxia (Fig. 1).
Recent studies using cultured cells, knockout, or
transgenic mice seemingly demonstrate that alterations
in the HIF system, whether decreases or increases in
aryl hydrocarbon nuclear translocator (ARNT; HIF-1b)
(21), HIF-1a (22–24), HIF-2a (21, 25), PHD1 (25), or von
Hippel-Lindau (26) levels, increase PPARa or PPARg
(22) in heart or skeletal muscle. Such apparently con-
tradictory studies necessitate a deeper understanding
of the cellular mechanisms whereby a decrease in
PPARa is absolutely required to maintain ATP levels
for the contractile function of the hypoxic heart. Here,
we show that hypoxia causes the heart to undergo a
series ofmetabolic changes, coordinated by PPARa and
designed to use the limited available oxygen as effi-
ciently as possible.Wedemonstrate in normalmice how
a high-fat diet increases PPARa expression, which
prevents the metabolic changes required for acclima-
tion to hypoxia, thereby significantly decreasing [ATP]
and myocardial contractile function. We also demon-
strate that the lack of myocardial PPARa prevents any
metabolic response to hypoxia and that chemical in-
duction of HIF, by inhibition of HIF hydroxylases in
mechanically active cardiomyocytes, has the same ef-
fect on PPARa as hypoxia. In short, for adaptation to
hypoxia, it is essential that PPARa expression decreases
to increase the efficiency of oxygen use, via orchestrated
changes in substrate metabolism and mitochondrial
respiration, so that normoxic [ATP] and cardiac func-
tion can be maintained.
MATERIALS AND METHODS
Animals
Male wild-type 129Ev/Sv (n = 106; 14 mo) and littermate
PPARa2/2 (n = 72) mice were housed on a 12 h light/dark
cycle and fed ad libitum. Themice, a kind gift fromDr. Frank J.
Gonzalez (National Institutes of Health, National Cancer
Institute, Bethesda, MD, USA), were bred in-house on a pure
129Ev/Sv background with 10 backcrosses. All procedures
conformed to ethical regulations of the United Kingdom
Home Office.
Hypoxia
Mice were housed in a glass-fronted hypoxia chamber (Bio-
Spherix, Parish, NY, USA), inwhichN2 replaced O2. Chamber
O2,monitored continuously,was used to regulate chamberN2
levels via a feedback system. Mice were fed laboratory chow
(7.5% fat) or a high-fat (55% fat) diet. To acclimatize mice to
hypoxia, chamber O2 was reduced in daily steps over a
7 d period to be maintained at 11% (v:v) for a further 12 d.
Following hypoxia, animals were reoxygenated for 1 h to
ameliorate any short-term effects of reoxygenation on cardiac
function.
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Cardiac MRI
MRI was carried out on an 11.7 T (500 MHz) vertical bore
(123-mm diameter) magnet (Magnex Scientific, Oxon, United
Kingdom), as previously described (27).
Heart perfusion
Mice were anesthetized using 60mg × kg bodyweight21 sodium
pentobarbitone intraperitoneally and hearts were excised and
arrested in ice-coldKrebs-Henseleit buffer.Heartswereperfused
in Langendorff mode at 80 mmHg perfusion pressure and at
37°C with modified Krebs-Henseleit recirculating buffer gassed
with 95% O2/5% CO2 containing 11 mM glucose and 0.4 mM
palmitate prebound to 1.5% (w/v) albumin. A polyethylene
balloon connected to a pressure transducer was inserted in the
left ventricle (LV) and inflated to an end-diastolic pressure of 4–8
mmHg to measure pressures and heart rates.
Cardiac substrate metabolism
Glycolytic flux and palmitate oxidation were measured in per-
fused hearts using 25 mCi [5-3H]-glucose or [9,10-3H]-palmitate,
respectively, in recirculating perfusion buffer, as previously de-
scribed (3, 28). Buffer samples were taken every 5 min for the
measurement of [3H] label conversion to 3H2OusingDowexanion
separation or Folch extraction. In a subset of experiments, insulin
(500mU)was added to the buffer tomeasure themaximal insulin-
stimulatedresponse.Heartsweresnapfrozen in liquidN2.Cardiac
lactateeffluxwasdeterminedbymeasuring lactate concentrations,
using lactate dehydrogenase, in timed buffer collections.
Cardiac high-energy phosphate metabolism
Perfusedheartswere inserted into the sameNMRsystemasused
for imaging (see Cardiac MRI section), but using a 10 mm di-
ameter probe (Rapid Biomedical, Wuerzburg, Germany). Fully
relaxed spectra were acquired by averaging 60 scans using a 90°
pulse (60 ms) and a 10-s delay to give an acquisition time of 10
min. Data were analyzed using jMRUI software and 4 spectra
were summed to determine ATP, PCr, and Pi peak areas. In-
tracellular pH, the cytosolic-free ADP ([ADP]free), and the free
energy of ATP hydrolysis (DGATP) were calculated as previously
described (4).
HL-1 cardiomyocyte culture
HL-1 murine cardiomyocytes, a kind gift from Dr. William C.
Claycomb (Louisiana State University Medical Center, New
Orleans, LA, USA), were maintained in Claycomb Medium
(Sigma-Aldrich, Dorset, United Kingdom). Cells were sup-
plemented with 10% fetal bovine serum, ascorbic acid
(0.3 mM), norepinephrine (0.1 mM), and L-glutamine (4 mM).
Cells were cultured on plates precoated with 5 mg/ml fibro-
nectin and 0.02% gelatin and incubated in 5%CO2 at 37°C and
95% humidity. All experiments were performed on conflu-
ent, beating cells. Cells were exposed to 2% hypoxia or nor-
moxia for 24 h. In separate experiments, normoxic HL-1 cells
were incubated for 24 h with a specific PHD inhibitor, 50 mM
Figure 1. Putative mechanism for the control of cardiac substrate metabolism and function in hypoxia. Decreased oxygen tension in the
blood inhibits PHD activity, stabilizing HIF-a subunits and down-regulating the nuclear hormone receptor, PPARa. In turn, PPARa
regulates fatty acid and glucose metabolism via changes in several proteins, including MCAD and PDK4, and the mitochondrial inner
membrane potential, viaUCP3 and mitochondrial thioesterase 1 (MTE-1) proteins. Increased glycolytic ﬂux and decreased mitochondrial
uncoupling increase the efﬁciency of ATP production, the ATP being consumed primarily by myocardial contraction. ANT, adenine
nucleotide translocase; CoA, coenzyme A; ETC, electron transport chain; FA, fatty acid; FADH2, ﬂavin adenine dinucleotide; LDH, lactate
dehydrogenase; NEFA, nonesteriﬁed fatty acid; PDH, pyruvate dehydrogenase; PGC-1a, PPARg coactivator a; Pi, inorganic phosphate;
RXR, retinoid X receptor; TCA, tricarboxylic acid.
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2-(1-chloro-4-hydroxyisoquinoline-3-carboxamido) acetic acid
(IOX3) (29, 30), which was synthesized specifically for the ex-
periment (31). Cells were aspirated with PBS and harvested for
protein analysis or quantitative RT-PCR (qRT-PCR).
qRT-PCR analysis of cardiac and skeletal muscle and
HL-1 cells
Primers were designed using Primer3 software based on
GenBankor EnsemblGenomes browser searches and obtained
from Eurofins MWG Operon (Wolverhampton, United King-
dom). References to primer sequences included the following:
PPARa, NM_011144.6; PPARb/d, NM_011145.3; PPARg,
NM_011146.3; MCAD, NM_007382.4; UCP3, NM_009464.3;
PDK4,NM_013743.2;VEGF,NM_009505.4;b-actin,NM_007393.3.
Total RNA was extracted and purified from frozen heart and
skeletal muscle tissues using a QiaAmp DNA Mini Kit (Qia-
gen, West Sussex, United Kingdom). For cells, total RNAwas
extracted and purified from #5 3 106 confluent HL-1 cells
using a QiaAmp kit (Qiagen). cDNA was synthesized from
the RNA template using a high-capacity transcriptase kit
(Thermo Fisher Scientific Life Sciences, Waltham, MA, USA).
Quantitative PCR amplification was performed using the
Real-Time PCR System (Thermo Fisher Scientific Life Sci-
ences). The PCR program had an initial heat-activation step of
95°C for 10 min. Forty cycles of thermocycling were per-
formed with a denaturation step at 95°C for 15 s and an
annealing and extension step at 60°C for 1 min. Fluorescence
was measured following each extension step. After amplifi-
cation, a melting curve was acquired and used to determine
the PCR product specificity. Relative quantification of target
gene expression was normalized to the housekeeping gene,
b-actin, and performed using a 22ΔΔCt method.
Tissue and cell lysate preparation
and immunoblotting
Powdered frozen cardiac or skeletal muscle was added to 300 ml
lysis buffer and homogenized for 30 s, as previously described
(3, 28). Confluent HL-1 cardiomyocytes in 6-well plates were
washed with PBS and added to 150 ml lysis buffer containing
protease inhibitor. Lysateswere boiled for 5min and centrifuged
at 13,000 rpm for 10 min, supernatant was saved, and protein
concentrations were determined using a bicinchoninic acid pro-
tein assay kit (Fisher Scientific, Loughborough, United King-
dom). Samples were stored at 280°C following addition of 5%
2-ME (v/v) and boiling for 5 min.
Equal concentrations of protein from cardiac and skeletal
muscle sampleswere loadedonto12%SDS-PAGEgels, separated
using electrophoresis, and transferred onto Immobilon-P mem-
branes (Millipore, Watford, United Kingdom). Cardiac and skel-
etalmuscle proteinswere detected using the followingpolyclonal
antibodies and dilutions in 5% milk: PGC-1a and MCAD (Santa
Cruz Biotechnology, Dallas, TX, USA), 1:500; GLUT1 (Abcam,
Cambridge, United Kingdom), 1:1000; GLUT4 (kind gift of
Geoffrey Holman, University of Bath, United Kingdom), 1:4000;
PDK4 and UCP3 (Abgent, Maidenhead, United Kingdom), 1:500
and 1:2500; MTE-1 (kind gift of Dr. Stefan Alexson, Karolinska
Institute, Stockholm, Sweden), 1:2000; RXRa (Santa Cruz Bio-
technology, London, United Kingdom), 1:1000; HIF-1 and -2a
(Novus Biologicals, Littleton, CO, USA), 1:2000 and 1:500.
Secondary antibodies were horseradish peroxidase conjugate
polyclonal with goat anti-rabbit specificity (Autogen-Bioclear,
Wiltshire, United Kingdom), all diluted to 1:3500, with the ex-
ception of GLUT1 and -4, HIF-1a (1:2000) and -2a (1:1000), and
MCAD (donkey anti-goat). Consistent protein loading and
transfer were confirmed by Ponceau staining and protein levels
related to internal standards to ensure homogeneity between
samples and gels. Bands were quantified using UN-SCAN-IT
software (Silk Scientific, Orem, UT, USA), and all samples were
run in duplicate on separate gels to confirm results.
Glycolytic enzyme activities
Themyocardial enzymatic activities of 3-phosphoglycerate kinase
(PGK) and pyruvate kinase (PK) were measured using coupled
enzyme assays (32). Frozen, ground heart tissue (1 mg/ml)
was extracted with the buffer containing 150 mM NaCl,
60mMTris-HCl, 5mMEDTA, 0.2%Triton-X 100, 1mMPMSF,
10 mg/ml leupeptin, 1 mg/ml aprotinin, pH 7.5. The PK ac-
tivity was assayed at 30°C, 340 nm in medium containing
50mM imidazole (pH 7.6), 20 mMKCl, 2 mMMgCl2, 0.1 mM
EDTA, 0.1 mM NADH, 1 mM ADP, 4.5 U/ml lactate de-
hydrogenase, and 1 mM phosphoenolpyruvate. The PGK
activity was recorded at 25°C, 340 nm, in an assay medium
containing 50 mM imidazole buffer (pH 7.6), 2 mM MgCl2,
0.1 mM EDTA, 1 mM ATP, 5 mM 3-phosphoglycerate, and
0.2 mM NADH.
Myocardial triacylglycerol assay
Cardiac lipids were extracted from freeze-clamped tissue (25–50
mg) using 10 ml 2:1 chloroform:methanol solution as previously
described (3, 28). After mixing and phase separation, the lower
phasewas air dried at 50°C and resuspended in ethanol.With the
use of a kit (Randox Laboratories, London, United Kingdom),
cardiac triacylglycerol (TAG) content was measured spectropho-
tometrically at 500 nm.
Statistics
Grouped data (means 6 SEM) were analyzed using 3-factor
ANOVAs, with individual comparisons subsequently per-
formed using Student’s t tests. Results were considered signifi-
cantly different at P, 0.05.
RESULTS
Effects of hypoxia on mouse physiology and
cardiac morphology
To investigate functional and metabolic responses of the in
vivomouse heart to hypoxia, we used a 3-wk protocol that
began with 7 d of lowering ambient oxygen concentration
from 21 to 11% in daily increments to produce a graded,
physiologichypoxia (Fig.2).Hypoxia inwild-type, chow-fed
mice increasedwhole-blood hemoglobin by 51% (P, 0.001)
and hematocrit by 33% (P , 0.001) but did not alter body
weight. Established HIF-1a downstream targets, cardiac
VEGF and PDK1 protein, increased 3.6-fold (P, 0.001) and
1.8-fold (P, 0.01), respectively. LVmass decreased by 19%
(P , 0.001) following hypoxia, whereas right-ventricular
(RV) mass was unaltered. Plasma metabolites in wild-type
mice were unchanged by hypoxia (Supplemental Fig. 1).
Effects of hypoxia on cardiac function and
metabolism in chow-fed, wild-type mice
Hypoxia in chow-fed, wild-type mice decreased cardiac
PPARa mRNA levels by 36% (P , 0.05), with PPARd
mRNA and PPARg, RXR, and PGC-1a protein levels
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remainingunchanged (Fig. 3AandSupplemental Fig. 2). In
parallel with lower PPARa mRNA levels, hypoxia de-
creased protein levels of downstream targets of PPARa:
UCP3, MTE-1, and PDK4 (Fig. 3B). MCAD protein levels
were 24% (P , 0.05) lower, but proteins involved in mi-
tochondrial respiration were unchanged following hyp-
oxia (Supplemental Fig. 2).
Hypoxia increased cardiac glycolysis 2.3-fold (P, 0.01)
and lactate efflux 2.4-fold (P, 0.01), measured in isolated,
beating, perfused hearts using [3H] substrate labeling (Fig.
3C). Hypoxia did not alter total cardiac GLUT4 protein or
activities of glycolytic intermediates (Supplemental Fig. 3).
Fatty acid oxidation was 26% (P , 0.02) lower in hearts
fromhypoxicmice comparedwith normoxic controls (Fig.
3D), whereas myocardial TAG levels were 28% (P, 0.05)
higher in hypoxic mice. In isolated, perfused hearts, [PCr]
was 31% (P , 0.001) lower, but [ATP] was unaltered by
hypoxia, measured using [31P] NMR spectroscopy and
HPLC (Fig. 3E); total Cr was 28% (P , 0.05) lower fol-
lowing hypoxia. Although [ADP]free increased 2-fold (P,
0.02), the calculated DGATP was preserved. In vivo cine
MRI showed that 3 wk of hypoxia did not alter cardiac
output, cardiac index, or ejection fraction, despite an 18%
(P, 0.02) lower stroke volume (SV), resulting from a 17%
(P , 0.05) lower end-diastolic volume (EDV) in hypoxic
mice (Fig. 3F).
Effect of hypoxia on cardiac function and
metabolism in high-fat–fed, wild-type mice
The cardiac metabolic and energetic changes observed in
hypoxicmicemayhavebeen causedbydecreasedPPARa
expression. To investigate whether PPARa expression is
central to hypoxic adaptation, we prevented PPARa
down-regulation by increasing PPARa expression using
high-fat (55% fat) feeding. The feeding of mice a high-fat
diet for 3 wk in normoxia did not alter body weight, but
with hypoxia, causeda 10% (P, 0.01) loss of bodyweight
and a 19% (P, 0.01) decrease in LVmass (Supplemental
Table 1). High-fat feeding increased PPARa mRNA
expression in both normoxia and hypoxia (P , 0.05),
preventing any hypoxia-induced decrease (Fig. 4A).
PPARdmRNA and PPARg, RXR, and PGC-1a protein
levels were unchanged by high-fat feeding. Down-
stream targets of PPARa, UCP3, and MTE-1 proteins,
increased 2-fold (P , 0.001), and MCAD protein in-
creased by 39% (P, 0.01) with high-fat feeding under
both normoxia and hypoxia (Fig. 4B and Supplemental
Fig. 2). High-fat feeding did not significantly increase
cardiac PDK4 protein, although it prevented the de-
crease caused by hypoxia in chow-fed mice.
High-fat feeding prevented the increase in cardiac
glycolysis and lactate efflux that occurred in chow-fed
mice in hypoxia, and decreased GLUT4 protein by 59%
(P , 0.05), which remained unaltered by hypoxia (Fig.
4C). High-fat feeding increased cardiac fatty acid oxi-
dation by 22% (P, 0.05; Fig. 4D) and myocardial TAG
content by 82% (P, 0.01), both unaffected by hypoxia.
High-fat feeding decreased cardiac [PCr] by 25% (P ,
0.05) in normoxic mice, but [PCr] did not decrease fur-
ther with hypoxia (Fig. 4E). [ATP] was normal in nor-
moxic high-fat–fedmouse hearts butwas 31% (P, 0.05)
lower in hearts from hypoxic high-fat–fed mice com-
pared with chow-fed normoxic mice. Total Cr was un-
altered in normoxic high-fat–fed hearts but was 37%
(P , 0.05) lower in hearts from high-fat–fed mice ex-
posed to hypoxia. [ADP]free was 55% (P , 0.05) higher
in hearts from normoxic high-fat–fed mice compared
Figure 2. Effect of 3 wk hypoxia on whole-body physiology (A)
and in vivo cardiac morphology (B) in wild-type mice fed a chow
diet; n = 6. S, septum. *P , 0.05 vs. normoxic chow-fed control.
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with normoxic chow-fed mice and increased by a fur-
ther 38% with hypoxia (P , 0.05). High-fat feeding
significantly lowered cardiacDGATP in allmouse hearts.
High-fat feeding under normoxia had no effect on
cardiac function (Fig. 4F), whereas feeding a high-fat
diet under hypoxia decreased in vivo cardiac output by
24% compared with normoxic chow (P, 0.01) or high-
fat-fed (P , 0.05) mice. This was a result of a 35% (P,
0.001) lower SV, accounted for by a 28% (P , 0.01)
lower EDV and despite a significantly higher heart
rate. The cardiac index was decreased by 15% (P ,
0.05), and ejection fractions were 12% (P, 0.02) lower
Figure 3. Effect of chronic hypoxia on cardiac metabolism and function. Effects of 3 wk of hypoxia on cardiac PPARa and PPARd
mRNA, plus PPARg, RXR, and PGC-1a proteins (A), PPARa-controlled proteins (B), myocardial carbohydrate and lipid metabolism (C,
D), [31P] MR spectra and high-energy phosphate metabolism (E), and in vivo cardiac function (F) in wild-type mice fed a (7.5% fat)
chow diet; min n = 6. *P, 0.05 vs. normoxic chow-fed control; minimum n = 6. gwwt, gram wet weight; mTAG, intramuscular TAG; Pext,
extracellular Pi; TCr, total Cr; ESV, end-systolic volume; b, beats; HR, heart rate.
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than in normoxic chow-fed mice. Hence, high-fat
feeding prevented the adaptive molecular and meta-
bolic responses to hypoxia that were observed in
chow-fed mouse hearts, thereby causing cardiac
dysfunction.
Effect of hypoxia on cardiac function and
metabolism in PPARa2/2 mice
Having demonstrated that increased PPARa was associ-
ated with impaired function of the hypoxic heart, we next
Figure 4. Effect of chronic hypoxia on cardiac metabolism and fuction in high-fat fed mice. Effects of a high-fat (55% fat) diet plus 3 wk
of hypoxia in wild-type mice on cardiac PPARa and PPARd mRNA, plus PPARg, RXR, and PGC-1a proteins (A), PPARa con-
trolled proteins (B), myocardial carbohydrate and lipid metabolism (C, D), [31P] MR spectra and high-energy phosphate metabolism
(E), and in vivo cardiac function (F); minimum n = 6. Data in gray show hypoxic response of chow-fed, wild-type mice for comparison.
*P , 0.05 vs. normoxic chow-fed control; †P , 0.05 vs. normoxic, high-fat–fed control.
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determined whether loss of PPARa altered cardiac meta-
bolic and functional responses to hypoxia. PPARa2/2mice
were fed a chow diet and housed under hypoxia for 3 wk.
PPARa2/2 mice had 13% (P , 0.05) lower body weight
and 18% (P , 0.05) lower LV mass than wild-type mice,
with neither altered by hypoxia (Supplemental Table 1).
Cardiac PPARa mRNA levels in PPARa2/2 mice were
negligible, although PPARdmRNAand PPARg, RXR, and
PGC-1a protein levels were normal and unchanged by
hypoxia (Fig. 5A and Supplemental Fig. 2). Cardiac UCP3
protein (Fig. 5B)was71%(P,0.001) lower, andMTE-1was
49%(P,0.02) lower inPPARa2/2mousehearts compared
withwild-typemice, andbothwereunchangedbyhypoxia.
Otherkeymitochondrialproteinswereunaltered relative to
wild-typemice (Supplemental Fig. 2). PDK4was45%lower
(P,0.01), andMCADproteinwas43%(P,0.001) lower in
normoxic and hypoxic PPARa2/2mouse hearts.
PPARa2/2 mouse hearts had 3-fold (P , 0.01) higher
glycolytic rates thannormoxicwild-typemouse hearts and
were unaffected by hypoxia (Fig. 5C). Glycolysis was not
maximal following hypoxia, as stimulation with insulin
doubled glycolytic rates in both normoxic and hyp-
oxic PPARa2/2mouse hearts (Supplemental Fig. 4). Lactate
efflux from hypoxic PPARa2/2mouse hearts was 2-fold
(P , 0.01) higher than from normoxic wild-type hearts
and not different from normoxic PPARa2/2 hearts. Car-
diacGLUT4 proteinwas similar in normoxic and hypoxic
PPARa2/2 mice. Consistent with PPARa being a regu-
lator of fatty acid metabolism, PPARa2/2mice had 24%
lower (P, 0.05) cardiac fatty acid oxidation (Fig. 5D) than
wild-typemice,whichwasunalteredbyhypoxia.Cardiac
TAGcontentwas increasedby45% (P, 0.05) innormoxic
and hypoxic PPARa2/2 mouse hearts. Thus, the lack of
PPARa prevented the metabolic changes that were ob-
served in hypoxic wild-type mouse hearts.
In PPARa2/2 mice, [PCr] was decreased by 43% (P ,
0.001), although [ATP] was unaltered compared with nor-
moxic wild-type mouse hearts (Fig. 5E). Hypoxic cardiac
[PCr] and [ATP]weredecreasedby51%(P,0.001) and34%
(P , 0.05), respectively, in PPARa2/2 mice. Total Cr was
decreased by 20% (P , 0.001) in PPARa2/2 mouse hearts
with no effect of hypoxia. As a consequence, [ADP]free was
2.7-fold (P,0.05)higherandDGATPsignificantly lower inall
PPARa2/2mouse hearts, and unaltered by hypoxia.
Normoxic PPARa2/2 mice had normal cardiac func-
tion, but hypoxic PPARa2/2 mice had 23% lower EDV
(P, 0.01), 19% lower ESV (P, 0.05), 29% (P, 0.01) lower
SV, and therefore, 20% lower cardiac output than nor-
moxic wild-type mice (Fig. 5F). Therefore, deletion of
PPARa significantly altered myocardial substrate and
energymetabolismandpreventedanymetabolic response
to hypoxia, thereby impairing cardiac function.
Effect of hypoxia on cardiac function and
metabolism in PPARa2/2mice fed a high-fat diet
To test whether high-fat feeding was operating via an al-
ternative mechanism to PPARa regulation, PPARa2/2
mice were fed a high-fat diet and housed in normoxia or
hypoxia. High-fat feeding had no effect on body weight or
LV mass compared with chow-fed PPARa2/2 mice
(Supplemental Table 1). Cardiac PPARa and PPARd
mRNA levels and PPARg and RXR protein concentrations
were unaltered by high fat feeding, being the same as in the
chow-fed PPARa2/2mice, with no effect of hypoxia (Fig.
6A). Cardiac UCP3, MTE-1, PDK4, and MCAD proteins
were unaltered in PPARa2/2 mice fed a high-fat diet
compared with a chow diet, again unaffected by chronic
hypoxia (Fig. 6B). Cardiac metabolism in PPARa2/2mice
was also unaltered by either high-fat feeding with or with-
out (Fig. 6C, D). Cardiac output in PPARa2/2 mice fed a
high-fat diet was 29% lower than chow-fed PPARa2/2
mice (P , 0.01) and 18% lower with hypoxia (P , 0.01),
similar to chow-fed PPARa2/2 mice exposed to chronic
hypoxia (Fig. 6E). Cardiac index was 29% lower in
PPARa2/2mice fed a high-fat diet vs. chow,with no effect
of hypoxia (P , 0.01). Ejection fraction was 6% lower in
high-fat–fed PPARa2/2 mice and unaltered by hypoxia
(P,0.05).Therefore,PPARa ablationnullified themetabolic
flexibility seen inhealthymice fed ahigh-fat diet, resulting in
impaired cardiac function and unaffected by hypoxia.
Effect of hypoxia and a high-fat diet on
whole-body physiology and PPARa-regulated
proteins in skeletal muscle
To investigate the weight loss observed in wild-type hyp-
oxicmice fed a high-fat diet (Supplemental Table 1), energy
intake was measured during the 3-wk protocol. Food con-
sumption was not affected by hypoxia or by the high-fat
diet (Fig. 7A). However, as a result of higher calorific value,
therewasa28%(P,0.05)higher energy intakeon thehigh-
fat diet, which again was unaffected by hypoxia. Cardiac
levels of UCP3 andMTE-1 were elevated by high-fat feed-
ing (Fig. 4B), suggesting that skeletal muscle UCPs
responded to the high-fat diet in a similar manner, thereby
contributing to body-weight loss in hypoxia. UCP3 protein
levels in skeletal (gastrocnemius) muscle were 26% (P ,
0.05) lower after 3wkofhypoxia (Fig. 7B andSupplemental
Fig. 5), a similar response to that in cardiacmuscle (Fig. 3B).
As found in cardiac muscle, UCP3 levels in skeletal muscle
increased with high-fat feeding compared with chow-fed
controls (P , 0.001) and were not altered by hypoxia.
Skeletal muscle MTE-1 protein levels showed identical re-
sponses to those of UCP3, being 34% (P , 0.05) lower in
hypoxic, chow-fed mice and 71% (P , 0.001) higher after
high-fat feeding with/without hypoxia. PDK4 protein lev-
els increased by 55% (P , 0.01) during high-fat feeding,
which again prevented the adaptive responses to hypoxia.
Effect of hypoxia or direct HIF activation on
HL-1 cardiac cells
Having established that adaptation to cardiac hypoxia
was regulated by PPARa, we used confluent, beating
HL-1 cardiac cells to investigate whether such adap-
tations were directly linked to the HIF system. Cells
were exposed to hypoxia (2% O2) for 24 h, or the HIF
system was chemically induced using 24 h incubation
with the selective prolyl hydroxylase inhibitor, IOX3
(33). Hypoxia caused a 5-fold increase in HIF-1a (P ,
0.001) and a 72% increase in HIF-2a (P , 0.05) protein
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levels (Fig. 8A and Supplemental Fig. 5). IOX3 was a
more potent activator of theHIF system than hypoxia,with
a 9-fold increase inHIF-1a (P, 0.001) anddoublingofHIF-
2a (P , 0.01) protein levels after 24 h incubation. Under
HIF-1a control, VEGFmRNA increased by 37% (P, 0.05)
in hypoxia and 59% (P , 0.001) with IOX3. PDK1 protein
levels increased 34% in hypoxia (P , 0.05) and 86% with
IOX3 treatment (P, 0.01). GLUT1 protein levels increased
Figure 5. Effects of 3 wk of hypoxia in PPARa2/2mice, fed a chow (7.5% fat) diet, on cardiac PPARa and PPARdmRNA, plus
PPARg, RXR, and PGC-1a proteins (A), PPARa controlled proteins (B), myocardial carbohydrate and lipid metabolism
(C, D), [31P] MR spectra and high-energy phosphate metabolism (E), and in vivo cardiac function (F ); minimum n = 6. Data
in gray show the hypoxic response of chow-fed, wild-type mice for comparison. *P , 0.05 vs. normoxic chow-fed control;
†P , 0.05 vs. normoxic PPARa2/2 chow fed.
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by 48% (P, 0.02) with hypoxia and 3-fold (P, 0.01) with
IOX3.
Hypoxia decreasedPPARamRNAby23% (P, 0.01) in
HL-1cells (Fig. 8B), similar to that causedby invivohypoxia
in the intact heart. IOX3 produced a similar, 25% decrease
in PPARamRNA (P, 0.001). PPARdmRNA levels were
unaffectedbyhypoxia or IOX3. PPARgmRNAlevelswere
not altered by hypoxia but were doubled (P, 0.001) after
IOX3 incubation.
In cultured cardiac cells, PPARa-controlledmRNA
expression was altered by hypoxia in a similar man-
ner as the respective protein in the in vivo hypoxic
heart (Fig. 8C). UCP3 levels were lowered by 27% (P,
0.01) by hypoxia butwere not altered by IOX3.MCAD
levels were 31% (P , 0.001) lower after hypoxia and
17% (P , 0.01) lower after IOX3. PDK4 levels were
unaffected by hypoxia or IOX3.
DISCUSSION
In this study, we have demonstrated that normobaric
hypoxia inmicedecreasedmyocardialPPARa expression,
fatty acid oxidation, and mitochondrial UCP3 and in-
creased carbohydrate metabolism; such changes allowed
normoxic [ATP] and contractile function to bemaintained.
Genetic ablation of PPARa in mice caused metabolic
changes in the normoxic mouse heart that were already at
the extremeofhypoxic adaptationand therefore, couldnot
be altered by hypoxia. A high-fat diet increased mouse
heart PPARa expression and prevented PPARa down-
regulation by hypoxia. Thus, with high-fat feeding, the
cardiac proteins under PPARa control (UCP3, MTE-1,
PDK4, and MCAD) and fatty acid oxidation increased,
whereas GLUT4 levels and glycolysis decreased; meta-
bolic changes that remained inhypoxia.Consequently, the
high-fat diet plus 3 wk exposure to hypoxia significantly
decreased myocardial [ATP], cardiac index, and ejection
fraction. To our knowledge, this is the first time that an
increase in a dietary constituent, fat, has been shown to
cause myocardial dysfunction in hypoxia, a finding that
may have implications for altitude exposure (34) or heart
failure (inwhich similarmetabolic changes, the “fetal gene
program,” occur) (1, 28, 35, 36). However, the human diet
typically contains ;30% fat and probably seldom the 7.5
or 55% fat used in the mouse diets.
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PPARa down-regulation and substrate switching
are essential for the maintenance of contractile function
of the hypertrophied heart (37), and there have been
reports of decreased PPARa expression in the heart
following in vivo hypoxia (24, 26–28). In our mice,
PPARa appeared to be the sole PPAR isoform involved
in the myocardial metabolic changes, as neither PPARd
nor PPARg levels changed. In agreement with findings
in human skeletal muscle at altitude (38), there were no
changes in PGC-1a nor were cardiac RXR protein levels
decreased significantly by hypoxia. In cultured car-
diomyocytes, however, others have demonstrated de-
creased hypoxia-induced PPARa/RXR DNA binding
as a result of decreased RXR (39) or increased HIF-1a
(24) levels. PPARa has been linked to hypoxic adapta-
tion in high-altitude tolerant humans (19), and simu-
lated hypoxia, using cobalt chloride to inhibit prolyl
hydroxylases (40), decreased PPARa mRNA (9), sug-
gesting regulation of PPARa via the HIF system. Cer-
tainly, in beating cardiomyocytes, we found that
hypoxia or prolyl hydroxylase inhibition increased
HIF-1a and HIF-2a, and decreased PPARa, MCAD,
and UCP3 expression; beneficial adaptations to hyp-
oxia (41).
Yet, studies of the HIF complex in transgenic (23) or
knockout mouse hearts (21, 22, 26) or skeletal muscle (25)
have yielded apparently conflicting (and confusing) re-
sults, in that decreased HIF-1b (21), HIF-1a (22, 23), or
HIF-2a (21) or increased HIF-1a (26) or HIF-2a (25) are
reported to increase (21, 23, 25) or not alter (22) PPARa or
decrease PPARg (22) expressionwith increased (21), or no
change in (25), fatty acidoxidation.Of course, these are not
studies on the metabolic effects of hypoxia, but on the
contributionof individual constituentsof theHIFpathway
to changes in metabolism via the PPAR transcription fac-
tors. So, both increased (25) and decreased (21) HIF-2a
increased PPARa expression, whereas decreased HIF-1a
increasedeitherPPARa (23)orPPARg (22) expression. It is
difficult to compare such studies, as few and rarely the
same measures of myocardial metabolism or function
have been made, and seldom using the same techniques.
However,most studies reported thedepositionof lipids
in the heart (21–23, 26) or cardiomyocytes (24), whether
Figure 7. Effect of 3 wk of hypoxia on energy intake (A; n = 4)
and skeletal muscle proteins (B; n = 6) under PPARa control
in wild-type mice fed chow (7.5% fat) or a high-fat (55% fat)
diet. *P , 0.05 vs. normoxic chow-fed control. gbwt, gram
body weight.
Figure 8. Effect of 24-h hypoxia or a PHD inhibitor, IOX3, on
HL-1 cardiomyocytes; n = 4. A) Hypoxic cell markers. B) PPAR
isoform expression. C) PPARa controlled mRNA expression.
*P , 0.05 vs. normoxic cells; †P , 0.05 vs. hypoxic cells. EPO,
Erythropoietin.
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HIF-1a was increased (24, 26) or decreased (22, 23). We
also found increased TAG in all hypoxic mouse hearts,
whether PPARa levels and fatty acid oxidation were in-
creased or decreased and unrelated to the effects of hyp-
oxia on contractile function. Indeed, both the high-fat–fed
and the PPARa2/2mouse hearts had high TAG levels in
normoxia thatwere unaltered by hypoxia, suggesting that
more fatty acidswere takenup thancould be oxidized and
that lipid deposits per se do not cause cardiac injury.
Carbohydratemetabolismwas increasedwithhypoxia,
but high-fat feeding prevented this potentially adaptive
mechanism. GLUT4 was down-regulated with activation
of PPARa via high-fat feeding and was unaltered by
chronic hypoxia. Consistent with this finding, PPARa
overexpression is known to repress GLUT4 mRNA (15),
and we have shown that cardiac GLUT4 content is re-
duced in obesity (42). Lower GLUT4 levels may have
contributed to cardiac dysfunction when hypoxia was
combined with a high-fat diet, preventing increased car-
bohydrate metabolism and resulting in lower cardiac
[ATP] in hypoxic mice.
Ventricularmasswas lower inchronicallyhypoxicmice,
resulting in cardiac hypotrophy. This reflects human
studies of altitude exposure in sea-level natives (12). The
stimulus for such reduction in LV mass, in the absence of
loss of body weight, may be a requirement to improve
oxygen diffusion distances in tissuewith a sustained, high-
oxygen demand (43). The molecular mechanisms associ-
ated with such loss of cardiac muscle are incompletely
understood butmay involve a reversal of the hypertrophic
mechanismsassociatedwithphysiologic hypertrophy (44).
In hypoxic mice fed a high-fat diet, whereas absolute LV
mass fell in hypoxia, cardiac hypotrophy was not evident,
as hypoxic high-fat–fed animals also lost bodyweight. The
molecular mechanisms for this weight loss are unclear;
however, all groups of PPARa2/2mice in this studywere
smaller than wild-type littermates, which potentially im-
plicates PPARa in the regulation of body weight.
Not only did hypoxia decrease PPARamRNA levels
and PPARa downstream targets—UCP3, MTE-1, and
MCAD protein levels—in the heart, but also in skeletal
muscle. In contrast to the increased PPARa observed in
skeletalmuscle in the PHD12/2mouse (25), the decrease
in PPARa expression is in agreement with findings in
human skeletal muscle at an altitude in which UCP3
levels and b-hydroxyacyl-coenzyme A dehydrogenase,
a b-oxidation enzyme and PPARa target, were down-
regulated (38). The adaptation to hypoxia via changes in
PPARa expression, observed here in heart and skeletal
muscle, may be relevant to other organs that have high
PPARa expression, such as liver, kidney, and intestine
(45). As in the heart, we found that the high-fat diet in-
creased (and prevented any hypoxia-induced decrease
in) UCP3, MTE-1, and PDK4 in mouse skeletal muscle.
Although the high-fat–fed mice consumed 28% more
calories than those on the chow diet, they did not gain
weight, possibly owing to energy wastage via increased
mitochondrial uncoupling (3).
The normobaric, hypoxia-induced decrease in cardiac
PCr in our mice has been shown in the human heart as a
decrease in PCr/ATP, measured using in vivo MRS: in
lowlanders following a trek to Mount Everest Base Camp
(12) and in Sherpa volunteers, even after 4 wk of de-
acclimation at low altitudes (11). The decreased cardiac
PCr/ATP in the Sherpa hearts was attributed to the re-
quirement for a higher [ADP]free, to be closer to the Km of
110 mM (46) for ADP-requiring PK activity in glycolysis,
reflecting the elevated contribution of carbohydrate-to-
myocardial energyneeds (7, 11). Suchamechanismmaybe
related to a decrease in PPARa levels via high-altitude
adaptation of the PPARA gene in Tibetans (19) and could
explain why the highest [ADP]free occurred in the highly
glycolytic PPARa2/2 mouse hearts in normoxia and
hypoxia.However, a genetic adaptation cannot explain the
18% decrease in myocardial PCr/ATP and diastolic dys-
function inhuman lowlanders after a trek toMountEverest
(12), which may have been exacerbated by the hypobaria
anda result of the requirement for increased [ADP]free, plus
the insulin resistance andelevatedepinephrineobserved in
the same cohort (47).
[ADP]free is a key metabolite controlling oxidative
phosphorylation (4), so it is possible that the decrease in
PCr in the hypoxic mouse hearts was a result of the need
for higher [ADP]free to stimulate mitochondrial respira-
tion and to increase glycolytic flux. The requirement for
oxygen would have been decreased in the hypoxic hearts
by the decrease in both fatty acid oxidation and mito-
chondrial uncoupling, with increased flux through py-
ruvate dehydrogenase and increased glucose oxidation,
all of which allowed [ATP] and contractile function to
remain at normoxic levels.
In the mice fed a high-fat diet in normoxia, myocardial
PCr decreased with no loss of total Cr to maintain normal
ATP levels and cardiac function despite the increased oxy-
gen required for fatty acid oxidation and increased oxygen
wastage via mitochondrial uncoupling. Such changes with
high-fat diets have been observed in human (48) and rat
hearts associated with decreased efficiency (3). However,
when the oxygen supply was restricted, the combination of
greater oxygen requirement for fatty acid oxidation, plus
oxygen wastage via increased mitochondrial UCP3 pro-
teins, significantly decreased ATP, cardiac index, and ejec-
tion fraction. Likewise, mice with a cardiac-specific ARNT
ablation had increased PPARa expression and fatty acid
oxidation with decreased ejection fraction (21).
The metabolic changes caused by hypoxia in wild-type
mouse hearts were found to have occurred already in
normoxic PPARa2/2 mouse hearts and did not change
further with hypoxia. PPARa2/2 mouse hearts main-
tained normal cardiac index and ejection fractions in hyp-
oxia, owing to high [ADP]free, high glycolytic flux, low
PDK4 (suggesting increased pyruvate dehydrogenase flux
and glucose oxidation), low fatty acid oxidation, and low
mitochondrial UCP3 andMTE-1 levels, all ofwhichwould
have resulted in the most efficient use of any available
oxygen. Thus, metabolism in the normoxic PPARa2/2
mouse heart may be viewed as at the extreme of hypoxic
adaptation, which increases resistance to ischemia (49, 50),
but may not support a high workload (51) with greater
hypertrophy and functional impairment following aortic
constriction (52). It is possible that the PPARa2/2 mouse
hearts may have had decreased ejection fractions, in
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addition to the lower cardiac output andhigher heart rates,
with a longer duration of hypoxia. As metabolism in
PPARa2/2 mouse hearts was at the limit of hypoxic ad-
aptation during normoxia, with no response to hypoxia,
the use of PPARa2/2 mice to validate PPARa as a HIF
target is questionable. For example, knockout mice with
decreased HIF-2a (HIF-1b2/2) (21), increased HIF-2a
(Phd12/2) (25), and decreased HIF-1a [NADPH oxidase
deficient (Tg Nox2/2) transgenic mice] (22) had their
metabolic phenotypes reversed in a double knockout
made by crossing with PPARa2/2mice.
In summary, we propose that decreased myocardial
PPARa expression is central to the metabolic changes re-
quired tomaintain contractile function in hypoxia.Ahigh-
fat diet increased PPARa expression, fatty acid oxidation,
and mitochondrial UCP levels—changes that were toler-
ated in normoxia, but decreased ATP and impaired car-
diac function in hypoxia. Finally, themetabolic changes in
normoxic PPARa2/2mouse heart can be viewed as at the
extremeofhypoxicmetabolic adaptation, in that theyhave
no metabolic response to hypoxia.
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